BindingDB logo
myBDB logout

195 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
6313919 6 C4-substituted 1-beta-D-ribofuranosylpyrazolo[3,4-d]pyrimidines as adenosine agonist analogues.EBI TBA
27836398 31 Discovery of 1,3-diethyl-7-methyl-8-(phenoxymethyl)-xanthine derivatives as novel adenosine AEBI North-West University
27933810 166 Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HTEBI National Institute of Diabetes and Digestive and Kidney Diseases
27485602 183 Similarities and differences in affinity and binding modes of tricyclic pyrimido- and pyrazinoxanthines at human and rat adenosine receptors.EBI Jagiellonian University Medical College
26776359 21 Carbamate substituted 2-amino-4,6-diphenylpyrimidines as adenosine receptor antagonists.EBI North-West University
26781932 109 Discovery of aminoquinazoline derivatives as human A(2A) adenosine receptor antagonists.EBI Merck Research Laboratories
26392370 66 1,3,7-Triethyl-substituted xanthines--possess nanomolar affinity for the adenosine A1 receptor.EBI North-West University
25915162 12 New Frontiers in Selective Human MAO-B Inhibitors.EBI Sapienza Universit£ di Roma
24815000 21 8-Substituted 2-alkynyl-N(9)-propargyladenines as A2A adenosine receptor antagonists.EBI Yamasa Corporation
24164628 186 Adenosine A2A receptor as a drug discovery target.EBI Merck Research Laboratories
9438021 97 Flavonoid derivatives as adenosine receptor antagonists: a comparison of the hypothetical receptor binding site based on a comparative molecular field analysis model.EBI National Institute of Diabetes
23245803 87 Synthesis and structure-activity relationships of 2-hydrazinyladenosine derivatives as A(2A) adenosine receptor ligands.EBI University of Bonn
23281824 118 Synthesis of (E)-8-(3-chlorostyryl)caffeine analogues leading to 9-deazaxanthine derivatives as dual A(2A) antagonists/MAO-B inhibitors.EBI Universit£ degli Studi di Parma
16392813 329 Design, synthesis, and structure-activity relationships of 1-,3-,8-, and 9-substituted-9-deazaxanthines at the human A2B adenosine receptor.EBI Universit£ di Bari
22468757 171 Medicinal chemistry of A3 adenosine receptor modulators: pharmacological activities and therapeutic implications.EBI Universit£ di Ferrara
21664729 142 Synthesis and biological activity of tricyclic cycloalkylimidazo-, pyrimido- and diazepinopurinediones.EBI Jagiellonian University Medical College
22486652 44 Optimization of adenosine 5'-carboxamide derivatives as adenosine receptor agonists using structure-based ligand design and fragment screening.EBI National Institute of Diabetes and Digestive and Kidney Diseases
24900277 36 Development of Polar Adenosine A2A Receptor Agonists for Inflammatory Bowel Disease: Synergism with A2B Antagonists.EBI TBA
20188574 141 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists.EBI University of Bonn
19569717 251 1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity.EBI Institute
18424135 131 Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists.EBI National Institute of Diabetes and Digestive and Kidney Diseases
15566292 153 Novel bicyclic piperazine derivatives of triazolotriazine and triazolopyrimidines as highly potent and selective adenosine A2A receptor antagonists.EBI Biogen Idec Inc.
15771453 22 Development of spin-labeled probes for adenosine receptors.EBI University of Bonn
15771443 94 Novel diamino derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.EBI Biogen Idec, Inc.
15267242 54 Synthesis and biological activity of new potential agonists for the human adenosine A2A receptor.EBI IIQAB (CSIC)
15084123 24 Novel amino acid derived natural products from the ascidian Atriolum robustum: identification and pharmacological characterization of a unique adenosine derivative.EBI University of Bonn
12646033 124 Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists.EBI Universit£ di Ferrara
11881988 16 Ribose-modified nucleosides as ligands for adenosine receptors: synthesis, conformational analysis, and biological evaluation of 1'-C-methyl adenosine analogues.EBI Universit£ di Camerino
11784146 9 2,5'-Disubstituted adenosine derivatives: evaluation of selectivity and efficacy for the adenosine A(1), A(2A), and A(3) receptor.EBI Leiden/Amsterdam Center for Drug Research
12139454 56 Imidazo[2,1-i]purin-5-ones and related tricyclic water-soluble purine derivatives: potent A(2A)- and A(3)-adenosine receptor antagonists.EBI University of Bonn
11262085 92 Thiazole and thiadiazole analogues as a novel class of adenosine receptor antagonists.EBI Vrije Universiteit
11170643 171 Design, synthesis, and evaluation of novel A2A adenosine receptor agonists.EBI University of Virginia
11708915 52 Neoceptor concept based on molecular complementarity in GPCRs: a mutant adenosine A(3) receptor with selectively enhanced affinity for amine-modified nucleosides.EBI National Institute of Diabetes and Digestive and Kidney Diseases
11170630 46 Nucleosides and nucleotides. 200. Reinvestigation of 5'-N-ethylcarboxamidoadenosine derivatives: structure-activity relationships for P(3) purinoceptor-like proteins.EBI Hokkaido University
10649980 52 N-cycloalkyl derivatives of adenosine and 1-deazaadenosine as agonists and partial agonists of the A(1) adenosine receptor.EBI Universit£ di Camerino
10841798 64 Methanocarba analogues of purine nucleosides as potent and selective adenosine receptor agonists.EBI National Institute of Diabetes
10821712 18 Quantized surface complementarity diversity (QSCD): a model based on small molecule-target complementarity.EBI NeoGenesis, Inc.
10212125 14 N6,5'-Disubstituted adenosine derivatives as partial agonists for the human adenosine A3 receptor.EBI Leiden/Amsterdam Center for Drug Research
10212124 26 5'-N-substituted carboxamidoadenosines as agonists for adenosine receptors.EBI Leiden University
9703464 40 Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists.EBI National Institute of Diabetes
9703463 102 Synthesis and biological activity of a new series of N6-arylcarbamoyl, 2-(Ar)alkynyl-N6-arylcarbamoyl, and N6-carboxamido derivatives of adenosine-5'-N-ethyluronamide as A1 and A3 adenosine receptor agonists.EBI Universit£ di Ferrara
9667957 5 Nucleosides and nucleotides. 177. 9-(6,7-dideoxy-beta-D-allo-hept-5- ynofuranosyl)adenine: a selective and potent ligand for P3 purinoceptor-like protein.EBI Hokkaido University
9438026 41 5'-substituted adenosine analogs as new high-affinity partial agonists for the adenosine A1 receptor.EBI Leiden/Amsterdam Center for Drug Research
9371242 54 N6-cyclopentyl-3'-substituted-xylofuranosyladenosines: a new class of non-xanthine adenosine A1 receptor antagonists.EBI University of Ghent
8576924 69 Novel N6-(substituted-phenylcarbamoyl)adenosine-5'-uronamides as potent agonists for A3 adenosine receptors.EBI Universit£ di Ferrara
8917655 72 6-phenyl-1,4-dihydropyridine derivatives as potent and selective A3 adenosine receptor antagonists.EBI National Institute of Diabetes
8863798 52 2-alkenyl and 2-alkyl derivatives of adenosine and adenosine-5'-N-ethyluronamide: different affinity and selectivity of E- and Z-diastereomers at A2A adenosine receptors.EBI Universit£ di Camerino
8709132 92 Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: selectivity for A3 receptors.EBI National Institute of Diabetes
7739005 143 2-Aralkynyl and 2-heteroalkynyl derivatives of adenosine-5'-N-ethyluronamide as selective A2a adenosine receptor agonists.EBI Universit£ di Camerino
7707320 99 Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors.EBI National Institute of Diabetes
7562934 38 Ribose-modified adenosine analogues as potential partial agonists for the adenosine receptor.EBI Leiden University
7658444 56 2-[N'-(3-arylallylidene)hydrazino]adenosines showing A2a adenosine agonist properties and vasodilation activity.EBI Universit£ di Milano
7752196 103 Structure-activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A3 adenosine receptors.EBI National Institute of Diabetes
7966162 39 Selective ligands for rat A3 adenosine receptors: structure-activity relationships of 1,3-dialkylxanthine 7-riboside derivatives.EBI National Institute of Diabetes
7932588 48 2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors.EBI National Institute of Diabetes
8246243 9 Photoisomerization of a potent and selective adenosine A2 antagonist, (E)-1,3-Dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine.EBI Kyowa Hakko Kogyo Co., Ltd.
8355252 54 Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance.EBI Kyowa Hakko Kogyo Co., Ltd.
1548682 126 8-Polycycloalkyl-1,3-dipropylxanthines as potent and selective antagonists for A1-adenosine receptors.EBI Kyowa Hakko Kogyo Co., Ltd.
1738138 62 Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.EBI NIDDK
1433217 31 Synthesis and biological activity of N6-(p-sulfophenyl)alkyl and N6-sulfoalkyl derivatives of adenosine: water-soluble and peripherally selective adenosine agonists.EBI National Institute of Diabetes
1732541 60 Nucleosides and nucleotides. 103. 2-Alkynyladenosines: a novel class of selective adenosine A2 receptor agonists with potent antihypertensive effects.EBI Hokkaido University
1501234 111 Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.EBI Kyowa Hakko Kogyo Co., Ltd.
1495019 57 Nucleosides and nucleotides. 112. 2-(1-Hexyn-1-yl)adenosine-5'-uronamides: a new entry of selective A2 adenosine receptor agonists with potent antihypertensive activity.EBI Hokkaido University
1619615 71 2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors.EBI Universit£ di Camerino
1613750 46 Nucleosides and nucleotides. 107. 2-(cycloalkylalkynyl)adenosines: adenosine A2 receptor agonists with potent antihypertensive effects.EBI Yamasa Shoyu Co., Ltd
1895305 75 N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor.EBI University of South Florida
1875349 94 Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines.EBI CIBA-GEIGY Corporation
2002461 37 1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists.EBI Center for Bio-Pharmaceutical Sciences
2002448 112 N6-substituted adenosine receptor agonists: potential antihypertensive agents.EBI Warner-Lambert Company
1766003 18 Activity of N6-substituted 2-chloroadenosines at A1 and A2 adenosine receptors.EBI University of South Florida
2374150 193 4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.EBI Pfizer Central Research
2362269 30 2-(Arylalkylamino)adenosin-5'-uronamides: a new class of highly selective adenosine A2 receptor ligands.EBI CIBA-GEIGY Corporation
2258897 23 A novel synthesis of xanthines: support for a new binding mode for xanthines with respect to adenosine at adenosine receptors.EBI Merrell Dow Research Institute
2754711 102 Sulfur-containing 1,3-dialkylxanthine derivatives as selective antagonists at A1-adenosine receptors.EBI NIDDK
2709373 63 Electrophilic derivatives of purines as irreversible inhibitors of A1 adenosine receptors.EBI NIDDK
2909748 18 N6-bicycloalkyladenosines with unusually high potency and selectivity for the adenosine A1 receptor.EBI Warner-Lambert Company
3385722 42 N6-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]adenosine and its uronamide derivatives. Novel adenosine agonists with both high affinity and high selectivity for the adenosine A2 receptor.EBI Warner-Lambert Company
3373486 44 Adenosine receptor agonists: synthesis and biological evaluation of 1-deaza analogues of adenosine derivatives.EBI Universit£ di Camerino
3336027 32 N6-(arylalkyl)adenosines. Identification of N6-(9-fluorenylmethyl)adenosine as a highly potent agonist for the adenosine A2 receptor.EBI Warner-Lambert Company
2441057 22 Binary drugs: conjugates of purines and a peptide that bind to both adenosine and substance P receptors.EBI TBA
3572985 28 N6-phenyladenosines: pronounced effect of phenyl substituents on affinity for A2 adenosine receptors.EBI TBA
2888894 32 N6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity.EBI Parke-Davis Pharmaceutical Research Division
3018244 91 N6-substituted N-alkyladenosine-5'-uronamides: bifunctional ligands having recognition groups for A1 and A2 adenosine receptors.EBI TBA
3005574 34 Ribose-modified adenosine analogues as adenosine receptor agonists.EBI TBA
2995663 26 N6-cycloalkyladenosines. Potent, A1-selective adenosine agonists.EBI TBA
6279840 53 Adenosine receptors: targets for future drugs.EBI TBA
12617898 13 Design, synthesis and binding affinity of 3'-fluoro analogues of Cl-IB-MECA as adenosine A3 receptor ligands.EBI Seoul National University
11392549 45 Ring-Constrained (N)-methanocarba nucleosides as adenosine receptor agonists: independent 5'-uronamide and 2'-deoxy modifications.EBI NIDDK
10714510 36 The discovery and synthesis of highly potent, A2a receptor agonists.EBI Glaxo Wellcome Medicines Research Centre
10999489 29 2-Nitro analogues of adenosine and 1-deazaadenosine: synthesis and binding studies at the adenosine A1, A2A and A3 receptor subtypes.EBI University of Amsterdam
9871585 23 Diimidazo[1,2-c:4',5'-e]pyrimidines: N6-N1 conformationally restricted adenosines.EBI Griffith University
9873707 18 Fluorescent probes for adenosine receptors: synthesis and biology of N6-dansylaminoalkyl-substituted NECA derivatives.EBI GlaxoWellcome Medicines Research Center
 31 New base-altered adenosine analogues: Synthesis and affinity at adenosine A1 and A2A receptorsEBI TBA
 22 High selectivity of novel isoguanosine analogues for the adenosine A1 receptorEBI TBA
22104008 64 Evaluation of molecular modeling of agonist binding in light of the crystallographic structure of an agonist-bound A2A adenosine receptor.EBI National Institute of Diabetes and Digestive and Kidney Diseases
20869242 46 Discovery of 2-aminoimidazopyridine adenosine A(2A) receptor antagonists.EBI Ligand Pharmaceuticals, Inc.
20537438 101 Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods.EBI East China University of Science and Technology
20116907 15 Synthesis and theoretical studies on energetics of novel N- and O- perfluoroalkyl triazole tagged thienopyrimidines--their potential as adenosine receptor ligands.EBI Institute of Chemical Technology
20304654 79 Synthesis and pharmacological characterization of a new series of 5,7-disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazine derivatives as adenosine receptor antagonists: A preliminary inspection of ligand-receptor recognition process.EBI National University of Singapore
19580286 44 Nucleoside-5'-monophosphates as prodrugs of adenosine A2A receptor agonists activated by ecto-5'-nucleotidase.EBI University of Bonn
 52 Adenosine A2A antagonists with potent anti-cataleptic activityEBI TBA
 8 Pyrazolo[3,4-d]pyrimidines: C4, C6 substitution leads to adenosine A1 receptor selectivityEBI TBA
 13 Discovery of FK453, a novel non-xanthine adenosine A1 receptor antagonistEBI TBA
 12 Pyrazolo[3,4-d]pyrimidines; adenosine receptor selectivityEBI TBA
 32 Synthesis of new pyrazolo[4,3-e]1,2,4-triazolo[1,5-c] pyrimidine and 1,2,3-triazolo[4,5-e]1,2,4-triazolo[1,5-c] pyrimidine displaying potent and selective activity as A2a adenosine receptor antagonists.EBI TBA
 52 The synthesis and biochemical evaluation of new A1 selective adenosine receptor agonists containing 6-hydrazinopurine moietiesEBI TBA
 8 An explanation of the substituent effect of 1,3,8-trisubstituted xanthines on adenosine A1/A2 affinity.EBI TBA
19140664 82 N-[6-amino-2-(heteroaryl)pyrimidin-4-yl]acetamides as A2A receptor antagonists with improved drug like properties and in vivo efficacy.EBI Neurocrine Biosciences
18835161 37 2,6-Diaryl-4-acylaminopyrimidines as potent and selective adenosine A(2A) antagonists with improved solubility and metabolic stability.EBI Neurocrine Biosciences
18723354 12 Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues.EBI North-West University
17602796 5 Synthesis and adenosine receptor binding studies of some novel triazolothienopyrimidines.EBI University College of Pharmaceutical Sciences
12398547 9 Lignans isolated from valerian: identification and characterization of a new olivil derivative with partial agonistic activity at A(1) adenosine receptors.EBI University of Bonn
9514015 6 Bioactive pyridoacridine alkaloids from the micronesian sponge Oceanapia sp.EBI Institut für Biowissenschaften
18329269 77 Synthesis of N-pyrimidinyl-2-phenoxyacetamides as adenosine A2A receptor antagonists.EBI Neurocrine Biosciences
18189346 21 Identification of novel, water-soluble, 2-amino-N-pyrimidin-4-yl acetamides as A2A receptor antagonists with in vivo efficacy.EBI Neurocrine Biosciences
17827019 86 Phenylethyl-substituted pyrimido[2,1-f]purinediones and related compounds: structure-activity relationships as adenosine A(1) and A(2A) receptor ligands.EBI Jagiellonian University Medical College
17499511 46 N9-benzyl-substituted 1,3-dimethyl- and 1,3-dipropyl-pyrimido[2,1-f]purinediones: synthesis and structure-activity relationships at adenosine A1 and A2A receptors.EBI Jagiellonian University
17381154 4 Neuroprotective principles from Gastrodia elata.EBI National Research Institute of Chinese Medicine
17236762 23 Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines.EBI Schering-Plough Research Institute
17125265 49 Tricyclic imidazoline derivatives as potent and selective adenosine A1 receptor antagonists.EBI Biogen Idec, Inc.
17125264 60 Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A1 receptor antagonists.EBI Biogen Idec, Inc.
16821798 62 A new synthesis of sulfonamides by aminolysis of p-nitrophenylsulfonates yielding potent and selective adenosine A2B receptor antagonists.EBI University of Bonn
16153830 64 Synthesis of [1,2,4]triazolo[1,5-a]pyrazines as adenosine A2A receptor antagonists.EBI Biogen Idec, Inc.
15978806 40 2-(2-Furanyl)-7-phenyl[1,2,4]triazolo[1,5-c]pyrimidin-5-amine analogs: highly potent, orally active, adenosine A2A antagonists. Part 1.EBI Schering-Plough Research Institute
15664803 46 Synthesis of alkyne derivatives of a novel triazolopyrazine as A(2A) adenosine receptor antagonists.EBI Biogen Idec Inc.
15341934 28 Triamino derivatives of triazolotriazine and triazolopyrimidine as adenosine A2a receptor antagonists.EBI Biogen Idec, Inc.
15341933 40 Studies on adenosine A2a receptor antagonists: comparison of three core heterocycles.EBI Biogen Idec, Inc.
15294001 88 Piperazine derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.EBI Biogen Idec, Inc.
14761205 56 Preparation, properties, reactions, and adenosine receptor affinities of sulfophenylxanthine nitrophenyl esters: toward the development of sulfonic acid prodrugs with peroral bioavailability.EBI University of Bonn
14741297 46 Synthesis and SAR evaluation of 1,2,4-triazoles as A(2A) receptor antagonists.EBI F Hoffmann-La Roche AG
12270178 74 Structure-affinity relationships of the affinity of 2-pyrazolyl adenosine analogues for the adenosine A2A receptor.EBI CV Therapeutics
12166943 81 1,2,4-Triazolo[5,1-i]purine derivatives as highly potent and selective human adenosine A(3) receptor ligands.EBI Nutrition Research Institute
12166930 21 Synthesis, biological properties, and molecular modeling investigation of the first potent, selective, and water-soluble human A(3) adenosine receptor antagonist.EBI TBA
12014951 139 Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions.EBI National Institute of Diabetes & Digestive & Kidney Diseases
11960496 50 5'-Deoxy congeners of 9-(3-amido-3-deoxy-beta-D-xylofuranosyl)-N(6)-cyclopentyladenine: new adenosine A(1) receptor antagonists and inverse agonists.EBI Ghent University
11906291 129 1,8-disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists.EBI University of Bonn
11454470 17 Substituted 4-phenyl-2-(phenylcarboxamido)-1,3-thiazole derivatives as antagonists for the adenosine A(1) receptor.EBI Leiden/Amsterdam Center for Drug Research
11206456 7 High-pressure synthesis of enantiomerically pure C-6 substituted pyrazol.EBI AstraZeneca R&D Griffith University
11150167 28 Fluorosulfonyl-substituted xanthines as selective irreversible antagonists for the A(1)-adenosine receptor.EBI Deakin University
11101355 26 7-Deazaadenines bearing polar substituents: structure-activity relationships of new A(1) and A(3) adenosine receptor antagonists.EBI University of Leipzig
11087559 7 Design, radiosynthesis, and biodistribution of a new potent and selective ligand for in vivo imaging of the adenosine A(2A) receptor system using positron emission tomography.EBI University of Milano-Bicocca
10737749 182 Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors.EBI National Institute of Diabetes
10669571 24 Water-soluble phosphate prodrugs of 1-propargyl-8-styrylxanthine derivatives, A(2A)-selective adenosine receptor antagonists.EBI University of Würzburg
10579811 70 Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as highly potent and selective human A(3) adenosine receptor antagonists.EBI Università degli Studi di Ferrara
10514293 31 Selective A(3) adenosine receptor antagonists: water-soluble 3, 5-diacyl-1,2,4-trialkylpyridinium salts and their oxidative generation from dihydropyridine precursors.EBI National Institute of Diabetes
10479279 20 N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects.EBI Novo Nordisk A/S
10450966 16 Discovery of FR166124, a novel water-soluble pyrazolo-[1,5-a]pyridine adenosine A1 receptor antagonist.EBI Fujisawa Pharmaceutical Co., Ltd.
10447949 27 Chiral resolution and stereospecificity of 6-phenyl-4-phenylethynyl- 1,4-dihydropyridines as selective A(3) adenosine receptor antagonists.EBI National Institute of Diabetes
10052977 82 Synthesis, CoMFA analysis, and receptor docking of 3,5-diacyl-2, 4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists.EBI National Institute of Diabetes
9873431 18 The synthesis of new adenosine A3 selective ligands containing bioisosteric isoxazoles.EBI Novo Nordisk A/S
9667972 119 Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) having high potency at the human A2B and A3 receptor subtypes.EBI National Institute of Diabetes
9622554 59 Design, synthesis, and biological evaluation of a second generation of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as potent and selective A2A adenosine receptor antagonists.EBI Università di Ferrara
9435909 90 Synthesis and structure-activity relationships of 3,7-dimethyl-1-propargylxanthine derivatives, A2A-selective adenosine receptor antagonists.EBI Julius-Maximilians-Universität Würzburg
9258367 99 Structure-activity relationships of 4-(phenylethynyl)-6-phenyl-1,4-dihydropyridines as highly selective A3 adenosine receptor antagonists.EBI National Institute of Diabetes
8863792 22 Synthesis and structure-activity relationship of pyrazolo[3,4-d]pyrimidines: potent and selective adenosine A1 receptor antagonists.EBI Griffith University
8863790 55 Derivatives of the triazoloquinazoline adenosine antagonist (CGS15943) are selective for the human A3 receptor subtype.EBI National Institute of Diabetes
8691445 70 Chiral pyrrolo[2,3-d]pyrimidine and pyrimido[4,5-b]indole derivatives: structure-activity relationships of potent, highly stereoselective A1-adenosine receptor antagonists.EBI Julius-Maximilians-Universität Würzburg
8676354 42 Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives: potent and selective A(2A) adenosine antagonists.EBI Università degli Studi di Ferrara
8576921 63 Interactions of flavonoids and other phytochemicals with adenosine receptors.EBI National Institute of Diabetes
8558508 55 Tetrahydrobenzothiophenone derivatives as a novel class of adenosine receptor antagonists.EBI National Institute of Diabetes
8496902 139 Structure-activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists.EBI National Institute of Diabetes
8410976 60 Effect of trifluoromethyl and other substituents on activity of xanthines at adenosine receptors.EBI National Institutes of Health
8230124 92 Synthesis of paraxanthine analogs (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: structure-activity relationships at adenosine receptors.EBI Pharmazeutische Chemie
7932565 92 Structure-activity relationships of 1,3-dialkylxanthine derivatives at rat A3 adenosine receptors.EBI National Institute of Diabetes
7731018 64 Tricyclic heteroaromatic systems. Synthesis and A1 and A2a adenosine binding activities of some 1-aryl-1,4-dihydro-3-methyl[1]benzopyrano[2,3-c] pyrazol-4-ones, 1-aryl-4,9-dihydro-3-methyl-1H-pyrazolo[3,4-b]quinolin-4- ones, and 1-aryl-1H-imidazo[4,5-b]quinoxalines.EBI Università di Firenze
3361572 38 Structure-activity profile of a series of novel triazoloquinazoline adenosine antagonists.EBI CIBA-GEIGY Corporation
3361571 30 [1,2,4]Triazolo[4,3-a]quinoxalin-4-amines: a new class of A1 receptor selective adenosine antagonists.EBI Warner-Lambert Company
3172141 35 Benzo[1,2-c:5,4-c']dipyrazoles: non-xanthine adenosine antagonists.EBI Merrell Dow Research Institute
3016270 40 Analogues of 1,3-dipropyl-8-phenylxanthine: enhancement of selectivity at A1-adenosine receptors by aryl substituents.EBI TBA
2795597 43 Linear and proximal benzo-separated alkylated xanthines as adenosine-receptor antagonists.EBI University of South Florida
2724296 113 Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions.EBI National Institutes of Health
2213835 66 7-Deaza-2-phenyladenines: structure-activity relationships of potent A1 selective adenosine receptor antagonists.EBI National Institute of Diabetes
2213834 56 Imidazodiazepinediones: a new class of adenosine receptor antagonists.EBI National Institute of Diabetes
2016719 68 1,3,8-trisubstituted xanthines. Effects of substitution pattern upon adenosine receptor A1/A2 affinity.EBI Nova Pharmaceutical Corporation
1992150 60 8-(Dicyclopropylmethyl)-1,3-dipropylxanthine: a potent and selective adenosine A1 antagonist with renal protective and diuretic activities.EBI Kyowa Hakko Kogyo Co., Ltd.
1895306 13 Synthesis and adenosine receptor affinity of a series of pyrazolo[3,4-d]pyrimidine analogues of 1-methylisoguanosine.EBI Griffith University
1694546 64 Structure-activity relationships of 8-cycloalkyl-1,3-dipropylxanthines as antagonists of adenosine receptors.EBI Vanderbilt University
1613758 95 (E)-1,3-dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonists.EBI Kyowa Hakko Kogyo Co., Ltd
1507211 28 Conformationally restrained, chiral (phenylisopropyl)amino-substituted pyrazolo[3,4-d]pyrimidines and purines with selectivity for adenosine A1 and A2 receptors.EBI Marion Merrell Dow Research Institute
25684690 22 Solid-Supported Synthesis and 5-HT7 /5-HT1A Receptor Affinity of Arylpiperazinylbutyl Derivatives of 4,5-dihydro-1,2,4-triazine-6-(1H)-one.BDB Jagiellonian University Medical College